OncoPrecision's Groundbreaking Presentation on ONC001
OncoPrecision Corporation, a leading name in developing advanced cancer therapies, has exciting news. The company has confirmed that their innovative development candidate, ONC001, will be featured in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting scheduled for December. This significant event brings together experts and innovators within the field of hematology to discuss the latest advancements in treatments and therapies for blood-related cancers.
Introduction to ONC001
ONC001 is a pioneering antibody-drug conjugate (ADC) specifically engineered to target CD64, a receptor that is commonly found in chronic myelomonocytic leukemia (CMML) and types of acute myeloid leukemia (AML) including the harder-to-treat M4 and M5 classifications. Through OncoPrecision's proprietary approach, this ADC has been crafted by leveraging insights from patient-derived biology combined with advanced artificial intelligence to better identify cellular vulnerabilities. This comprehensive strategy has resulted in the development of a lead antibody that exhibits high binding affinity, paired with optimal payload and linker chemistries aimed at reducing toxicity to other healthy cells.
Preclinical Findings to be Shared
During the presentation, Dr. Gastón Soria, Co-Founder and Chief Scientific Officer of OncoPrecision, will share compelling preclinical results illustrating the efficacy of ONC001. The findings will touch upon:
- Specific targeting of patient-derived CMML and AML cells
- Significant effectiveness in resistant samples that do not respond to existing therapies
- Impressive performance in both heterotopic and orthotopic models
These results highlight ONC001's potential as a game-changer in the battle against these challenging forms of leukemia.
What This Means for Cancer Therapy
As highlighted by Tarek Zaki, Co-Founder and Chief Executive Officer of OncoPrecision, the recognition of ONC001 for this prestigious oral presentation at ASH reflects the innovative nature of their therapeutic approach. The company is committed to tackling resistance mechanisms found in aggressive blood cancers, ultimately providing new treatment avenues for patients facing common but severe treatment failures in current oncology practices.
Details of the Oral Presentation
During the session entitled 'Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms,' Dr. Soria will present:
- Title: ONC001: A first-in-class ADC targeting CD64 for the treatment of monocytic leukemia developed through patient-guided target and payload selection
- Presenter: Gastón Soria, PhD, Co-Founder & Chief Scientific Officer, OncoPrecision
- Date: Saturday, December 6
- Session Time: 4:00 PM – 5:30 PM
- Presentation Time: 5:15 PM – 5:30 PM
- Location: OCCC – Valencia Room W415D
About OncoPrecision
OncoPrecision defines itself as a next-generation oncology therapeutics company that utilizes patient-driven biological research combined with AI-powered discovery platforms. By integrating advanced biological data and machine learning, OncoPrecision aims to develop precision medicines that enhance clinical success rates. The company is also keen on strategic partnerships to expedite the development and commercialization of its innovative programs.
Frequently Asked Questions
What is ONC001?
ONC001 is a first-in-class antibody-drug conjugate designed to target the CD64 receptor present in certain leukemia types.
What will be shared at the ASH Annual Meeting?
Dr. Soria will present preclinical data showcasing ONC001's efficacy against resistant leukemia cells.
Why is ONC001 significant?
This ADC represents a new strategy to overcome treatment-resistant blood cancers, offering hope to patients with limited options.
How does OncoPrecision develop its therapies?
The company uses patient-derived biology insights and advanced AI technologies to inform its therapeutic designs.
What is the focus area of OncoPrecision?
OncoPrecision specializes in treatments for hematologic malignancies and solid tumors, aiming for precision and effectiveness.
